LIST OF FIGURES 
FIGURE 1 Principle of Tumor Lymphokine Approach (y-IFN) 30 
FIGURE 2 Diagrammatic Structure of Retroviral Provector DNAs 31 
FIGURE 3 Structure of MLV Expression Vectors Used to Make PCLs 32 
FIGURE 4 Protein Immunoblot Analysis of retroviral PCLs DA and DX 33 
FIGURE 5 Southern Blot Analysis of Huy-Transduced Cells 34 
FIGURE 6 y-IFN Gene-Modified Tumor Cell Lines Express Increased 
Levels of MHC Class 1 35 
FIGURE 7 FACS Analysis of Class I MHC Levels in Murine Tumor Cells 36 
FIGURE 8 L33 Fibrosarcoma, B16F10 Melanoma, CT26 Colorectal 
Carcinoma, and Lewis Lung Tumor Are Substantially Less 
Tumorigenic in Syngeneic Mice When Gene-Modified with y-IFN 37 
FIGURE 9 Tumorigenicity in Athymic Nude Mice of L33 Fibrosarcom 
and B16F10 Melanoma Cells Transduced with y-IFN 38 
FIGURE 10 Injection of y-IFN Gene-Modified B16F10 Cells Generates 
Anti-Tumor Cell Mediated Cytotoxic Activity 39 
FIGURE 1 1 Injection of y-IFN Gene-Modified CT26 Generates Anti-Tumor 
Cell Mediated Cytotoxic Activity 40 
FIGURE 12 Injection of y-IFN Gene-Modified Lewis Lung Cells Generates 
Anti-Tumor Cell Mediated Cytotoxic Activity 41 
FIGURE 13 Vaccination with y-IFN Gene-Modified, but not Unmodified, 
B 16F10 Cells Results in Protection of Mice Against Subsequent 
Challenge with the Unmodified Parent Tumor 42 
FIGURE 14 Transduction of Human Melanoma Cell Lines 43 
FIGURE 15 MHC Expression in Transduced Human Melanoma Cell Lines 44 
FIGURE 16 Recognition of Gene- Modified Melanoma by HLA Restricted 
Melanoma Specific CTLs 45 
Recombinant DNA Research, Volume 17 
[617] 
